NCT02039219View on ClinicalTrials.gov

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 3, 2014

Primary Completion Date

July 30, 2017

Study Completion Date

January 29, 2018

Conditions
Alcoholic Hepatitis
Interventions
DRUG

Placebo

1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.

DRUG

10 mg Obeticholic Acid (OCA)

10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.

Trial Locations (4)

19141

Einstein Healthcare Network, Philadelphia

23298

Virgina Commonwealth University, Richmond

46202

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

Intercept Pharmaceuticals
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Intercept Pharmaceuticals

INDUSTRY

lead

Naga P. Chalasani

OTHER